Answers are grounded in this paper and cite their sources.
Preclinical evaluation of [124I]I-cobimetinib shows potential for noninvasive imaging of MEK-activated tumors, implying improved cancer treatment monitoring.
We report the synthesis, radiolabeling, and preclinical evaluation of [ 124 I]I-cobimetinib, a novel PET radiotracer for imaging MAPK pathway-driven tumors. Cobimetinib was converted to its boron pinacol ester (Bpin-cobimetinib) in 82 % yield, with >98 % purity confirmed by NMR, HRMS, and elemental analysis. Copper-mediated radioiodination of the Bpin precursor afforded [ 124 I]I-cobimetinib with >98 % radiochemical purity and 64 ± 8 % isolated radiochemical yields ( n = 6, range: 56–74 %) across multiple syntheses. The radiotracer showed high lipophilicity (logD = 3.4 ± 0.2) and excellent in vitro stability in PBS (90.1 ± 0.8 % intact at 72 h) and serum (81.2 ± 0.5 % intact at 72 h). In vitro , [ 124 I]I-cobimetinib displayed potent MEK-dependent cytotoxicity, with IC 50 values of 0.30 ± 0.08 μM in KRAS/BRAF-mutant lines versus 2.76 ± 0.55 μM in MAPK-low cells, and exhibited 2.5–4.5-fold higher cellular uptake in MAPK-driven models. In tumor-bearing mice, [ 124 I]I-cobimetinib rapidly accumulated in tumors (2.9 ± 0.48 %ID/g at 2 h, 6.4 ± 0.6 %ID/g at 48 h) with high tumor-to-blood (7.2) and tumor-to-muscle (14.9) ratios, while blocking studies confirmed MEK-specific uptake. Low thyroid uptakes (1.2–2.3 %ID/g over 96 h) indicated limited in vivo deiodination. PET/CT imaging showed intense tumor localization with minimal background, demonstrating robust in vivo retention (SUVmean = 3.8 ± 0.4; SUVmax = 5.6). These results establish [ 124 I]I-cobimetinib as a selective, stable PET tracer for noninvasive imaging of MEK-activated tumors, supporting its potential for tumor characterization and therapy monitoring in MAPK pathway driven cancers.
No takes yet. Share an insight, caveat, or question.
Amjad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: